Studies conducted thus far in prostate cancer provide evidence that in cells with a gain of function in Akt due to loss of PTEN activity, the transcriptional activity of NF-κB is upregulated, and inhibition of Akt interferes with this upregulation of NF-κB [26,27,28]. The gene discussed is AKT1; the disease is prostate carcinoma.